Who are Zanaflex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Moxonidin, Tenex, Precedex, Catapres-Tts-1, Catapresan TTS 2, low dose clonidine HCl sustained release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tizanidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Zanaflex — Competitive Intelligence Brief

Zanaflex (TIZANIDINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central alpha-2 Adrenergic Agonist. Area: Neuroscience.

marketed Central alpha-2 Adrenergic Agonist Nischarin Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Zanaflex (TIZANIDINE) — Legacy Pharma Usa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zanaflex TARGET	TIZANIDINE	Legacy Pharma Usa	marketed	Central alpha-2 Adrenergic Agonist	Nischarin	1996-01-01
Moxonidin	MOXONIDINE		marketed	moxonidine	Nischarin	1991-01-01
Tenex	GUANFACINE	Promius Pharma	marketed	Central alpha-2 Adrenergic Agonist	Nischarin	1986-01-01
Precedex	dexmedetomidine	Bioxcel	marketed	Central alpha-2 Adrenergic Agonist	Alpha-1D adrenergic receptor	1999-01-01
Catapres-Tts-1	CLONIDINE	Lavipharm	marketed	Central alpha-2 Adrenergic Agonist	Alpha-2A adrenergic receptor	1974-01-01
Catapresan TTS 2	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
low dose clonidine HCl sustained release	low dose clonidine HCl sustained release	Addrenex Pharmaceuticals, Inc.	phase 3	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-17 — Catapres-Tts-1 · 8337890 · Formulation · US
2031-09-08 — Catapres-Tts-1 · 8623409 · Formulation · US

Sponsor landscape (Central alpha-2 Adrenergic Agonist class)

Bioxcel · 1 drug in this class
Lavipharm · 1 drug in this class
Legacy Pharma Usa · 1 drug in this class
Promius Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zanaflex — Competitive Intelligence Brief. https://druglandscape.com/ci/tizanidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab